Opna Bio Announces Phase 1 Data for OPN-2853 in Myelofibrosis
09 Dec 2024 //
BUSINESSWIRE
Opna Bio to Present Data at ASH on BET Inhibitor in Myelofibrosis
13 Nov 2024 //
BUSINESSWIRE
Opna Bio Doses First Patient In Phase 1 Study Of OPN-6602 For Multiple Myeloma
26 Aug 2024 //
BUSINESSWIRE
Opna Bio Presents Preclinical Data on OPN-6602 and OPN-9840 at AACR
10 Apr 2024 //
BUSINESSWIRE